All Posts Tagged With: "MITI"
(MITI) Micromet Analyst Maintains Neutral on Shares
We have maintained a Neutral rating on Micromet, Inc. (MITI) with a target price of $7.00 per share following appraisal of third quarter 2011 results.
Micromet’s third quarter 2011 loss per share...
(MITI) Micromet Begins New Trial
Micromet Inc. (MITI) recently announced that it has begun a mid-stage registrational trial of its lead pipeline candidate, blinatumomab, in adult patients with B-precursor relapsed refractory acute lymphoblastic...
(MITI) Micromet Loss Less Than Analyst Estimates – Revenues Rise
Micromet Inc.’s (MITI) second quarter 2011 loss per share came in at 19 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 15 cents per share (also adjusting...
(MITI) Micromet Analyst Maintains Neutral on Shares
We have maintained a Neutral rating on Micromet, Inc. (MITI) with a target price of $6.00 per share.
We believe Micromet’s lead pipeline candidate, blinatumomab, holds tremendous potential in the...
(SNY) Sanofi-Aventis Announces Agreement to Acquire TargaGen
Sanofi-Aventis (SNY) continues to work on expanding its oncology portfolio with the company recently entering into an agreement to acquire TargaGen Inc. TargaGen, a privately-held US biopharmaceutical company,...
(MITI) Micromet’s Quarterly Report Shows Loss Increase
Micromet’s (MITI) first quarter fiscal 2010 loss per share came in at 23 cents, greater than the year-ago quarter’s loss of a penny. However, after adjusting for the change in fair value of warrants,...
(MITI) Micromet Announces 10 Million Share Stock Offering
Recently, Micromet (MITI) announced a 10 million share offering of common stock. In Aug 2009, Micromet received net proceeds of about $75 million from a common stock issuance.
We believe with the advancement...
(MITI) Micromet’s Fourth Quarter Loss Greater Than Expectations
Micromet’s (MITI) fourth quarter loss per share came in at 34 cents, wider than the Zacks Consensus Estimate of 18 cents and a loss of 12 cents reported in the prior-year period. For 2009, the company reported...
(MITI) Micromet Incorporated – Bear of the Day
Micromet’s (MITI) third quarter loss per share came in at $0.22, wider than the Zacks Consensus Estimate of $0.14.
Micromet’s re-acquisition of blinatumomab rights from MedImmune is of...
(MITI) Micromet’s Pipeline Impresses
We have been waiting for final phase II data on Micromet’s (MITI) lead pipeline candidate blinatumomab, which was presented earlier this month at the American Society of Hematology (ASH) meeting. The company’s...
(MITI) Micromet & Bayer Take a BiTE
Micromet (MITI), a biopharmaceutical company, is dependent on many of its collaborating partners for its product portfolio. In this respect, the company received good news with Bayer exercising its option...
(MITI) Micromet Misses Estimates
Micromet’s (MITI) third-quarter loss per share came in at 22 cents, well below the Zacks Consensus Estimate of 14 cents and a loss of 15 cents in the prior-year period. The company reported revenues of...